Search clinical trials for: Cryopreserved Ovarian Tissue

Total 66369 results

ABM Therapeutics Corporation

Terminated

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Advanced Solid Tumor | BRAF V600 Mutation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
National Cancer Institute (NCI)
Abbott

Active, not recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Liver Failure | Melanoma | Renal Failure | Breast Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Esophageal Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Malignant Head and Neck Neoplasm | Carcinoma of Unknown Primary | Malignant Testicular...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Exelixis

Terminated

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

SCLC | Breast | Ovarian | Gastric Cancers

United Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Grade 3 Endometrial Endometrioid Adenocarcinoma | Malignant Mixed Mesodermal (Mullerian) Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

Lynch Syndrome | Hereditary Breast Carcinoma | Hereditary Ovarian Carcinoma

United States
University of California, Los Angeles
Oregon Health and Science University

Completed

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Polycystic Ovary Syndrome (PCOS)

United States
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Advanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast Cancer

Belgium, Netherlands, United Kingdom
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Medikine, Inc.

Terminated

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)

Advanced or Metastatic Solid Tumors

United States
Rhizen Pharmaceuticals SA

Completed

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Solid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal Cancer

Czechia, Poland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Exelixis

Completed

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cancer | Solid Tumors

United States, Taiwan, Belgium, Israel, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Endometrial Adenosquamous... and other conditions

United States, Canada
Comprehensive Support Project for Oncology Research

Active, not recruiting

Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer

Stomach Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Endometrial Cancer | Liver Cancer

Japan
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01)

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Italy, Spain, United States, France, Korea, Republic of, Japan, Canada, Denmark, Belgium
Nerviano Medical Sciences

Active, not recruiting

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

United States, United Kingdom, China, Italy, Bulgaria, Hungary
Pfizer

Terminated

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001)

Breast Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms

United States, Puerto Rico
Sanguine Biosciences

Completed

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Depression | Melanoma | Epilepsy | Lymphoma | Multiple Sclerosis | Kidney Cancer | Cervical Cancer | Diabetes Mellitus | Leukemia | Breast Cancer | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Parkinson's Disease | Systemic Lupus Erythematosus | Multiple Myeloma | Hepatitis B | Insomnia | Colorectal Cancer | HIV/AID... and other conditions

United States
Jazz Pharmaceuticals

Active, not recruiting

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

HER2-expressing Cancers

United States, Canada, Korea, Republic of
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Technical University of Munich

Completed

Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers (LIBRE)

Hereditary Breast and Ovarian Cancer

Germany
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital

Terminated

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Lynch Syndrome | Hereditary Breast and Ovarian Cancer

United States
Carisma Therapeutics Inc

Active, not recruiting

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Adenocarcinoma | Stomach Neoplasms | Cancer | Breast Cancer | Head and Neck Cancer | Carcinoma, Hepatocellular | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Carcinoma, Transitional Cell | Breast Neoplasm | Prostate Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer and other conditions

United States
M.D. Anderson Cancer Center
AstraZeneca

Active, not recruiting

Selumetinib and Olaparib in Solid Tumors

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs

United States
Pfizer

Terminated

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Melanoma | Sarcoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Renal Cell Cancer | Hepatocellular Cancer | Squamous Cell Carcinoma | Non-Small-Cell Lung Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Active, not recruiting

Endocrine Disruptors and Life STILe in Breast Cancer Development (STILVARCA)

Breast Cancer | Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Life Style | Cadmium Exposure

Italy
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Canada, Italy, Japan, Portugal, Spain, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Advanced Cancer

United States, Australia, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States, Puerto Rico
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Icahn School of Medicine at Mount Sinai; Weill Medical College...

Active, not recruiting

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Kidney Cancer | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Colon Cancer

United States
AtlasMedx, Incorporated

Active, not recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Homologous Recombination Deficiency | Advanced Malignant Neoplasm

United States
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Bladder Urothelial Cancer | Endocervical...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

BRCA1 Syndrome | BRCA2 Syndrome | No Evidence of Disease | Hereditary Ovarian Carcinoma | Hereditary Female Breast Carcinoma

United States
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States
Epizyme, Inc.

No longer available

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Renal Cell Carcinoma | Malignant Mesothelioma | Chondrosarcoma | Synovial Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumor | Poorly Differentiated Chordoma | Malignant Rhabdoid Tumor of Ovary | Epithelioid Malignant Peripheral Nerve Sheath Tumor | Sinonasal Carcinoma | Spindle Cell Sarcoma | Epithelioid... and other conditions
Ikena Oncology
Gilead Sciences

Terminated

A Study of PY314 in Subjects With Advanced Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Gynecologic Cancer | Colorectal Cancer | Ovarian Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

United States
Haihe Biopharma Co., Ltd.

Terminated

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Solid Tumor | Prostate Cancer | Endometrial Cancer

United States, Australia, China
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States
Seagen Inc.

Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Colorectal Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Pseudomyxoma Peritonei | Carcinoma, Non-Small Cell Lung | Gastroesophageal Junction Carcinoma | HER2 Negative Breast Neoplasms | Exocrine Pancreatic Adenocarcinoma | Appendiceal...

United States, United Kingdom, Canada, Spain, France, Italy
City of Hope Medical Center

Active, not recruiting

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Unspecified Childhood Solid Tumor, Protocol Specific | Solid Tumor | Ewing Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Adult Brain Tumor | Recurrent... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Premenopausal

United States
NeoImmuneTech
Merck Sharp & Dohme LLC

Active, not recruiting

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)

Small Cell Lung Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Microsatellite Stable Colorectal Cancer | Any Advanced Solid Tumors

United States

Search clinical trials for: Cryopreserved Ovarian Tissue

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations